$ARQQ

Feenan Paul sold $12K of ARQQ

Feenan Paul (Chief Revenue Officer) sold 506 shares of Arqit Quantum Inc. (ARQQ) at $24.47 across 3 trades on 2026-10-02.

Original reporting
SEC EDGAR · Feenan Paul
Published Oct 6, 2026, 11:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQQ
Bearish
medium confidence
Mentioned
$ARQQ
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQQBearishLow
01

Why it matters

The disclosed sale is modest in size and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

02

Market read

A routine insider sale with limited market impact; useful for tracking insider activity.

03

What to watch

The insider still holds a sizable position; market may view the sale as non-material.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 disclosures provide primary source data on insider transactions.

Company-level read

Ticker impact

$ARQQBearishMedium confidence
Context

Form 4 filing shows Chief Revenue Officer sold 506 shares for $12,384, reducing his stake to 20,915 shares.

Expected impact

likely modest downward pressure as market prices in the insider sell

Evidence & confidence

The sale is small relative to float but signals possible insider sentiment; no 10b5-1 plan suggests discretionary sale.

Market effects

Minimal impact on quantum computing sector; isolated insider transaction.

No regional effect.

Negligible.

Counterpoint

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Arqit Quantum Inc.

    Quantum communications firm listed on NASDAQ under ARQQ.

  • Feenan Paul

    Chief Revenue Officer of Arqit Quantum, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QNTMedAI 9/10

Quantum Computing Shares Sink Ahead Of Blockbuster Quantinuum IPO

Quantinuum (QNT) shares fell Wednesday as the Honeywell-backed firm neared its Nasdaq debut, with pricing set for June 3 and first trading expected June 4. The company plans to sell 26.5 million shares at $53–$55 to raise about $1.46 billion, valuing it at up to $14.3 billion, according to the report. Other quantum stocks also declined.

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).